Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study

BACKGROUND In TANGO, switching to dolutegravir/lamivudine was non-inferior at 48 weeks to continuing 3-/4-drug tenofovir alafenamide-based regimens in virologically suppressed individuals with HIV-1. Antiretroviral agents have been associated with weight gain and metabolic complications. SETTING 134 centers; 10 countries. METHODS We assessed weight; fasting lipids, glucose, and insulin; and prevalence of insulin resistance and metabolic syndrome at baseline and Week 48 in TANGO participant subgroups by boosting agent use in baseline regimens (boosted and unboosted). RESULTS In each treatment group, 74% of participants used boosted regimens at baseline. In boosted and unboosted subgroups, weight and fasting glucose changes at Week 48 were small and similar between treatment groups. Overall and in the boosted subgroup, greater decreases from baseline were observed with dolutegravir/lamivudine in fasting total cholesterol (P<0.001), low-density lipoprotein cholesterol (P<0.001), triglycerides (P<0.001), total cholesterol/high-density lipoprotein cholesterol ratio (overall, P=0.017; boosted, P=0.007), and insulin (boosted, P=0.005). Prevalence of HOMA-IR ≥2 was significantly lower at Week 48 with dolutegravir/lamivudine overall (adjusted odds ratio [aOR; 95% CI], 0.59 [0.40-0.87]; P=0.008) and in the boosted subgroup (0.56 [0.36-0.88]; P=0.012) but not in the unboosted subgroup (0.70 [0.31-1.58]; P=0.396). Prevalence of metabolic syndrome at Week 48 was low and consistent between treatment groups overall, with differences trending to favor dolutegravir/lamivudine in the unboosted subgroup (aOR [95% CI], 0.41 [0.15-1.09]; P=0.075). CONCLUSION Generally, switching from 3-/4-drug tenofovir alafenamide-based regimens to dolutegravir/lamivudine improved metabolic parameters, particularly when switching from boosted regimens. Because of smaller sample size in the unboosted subgroup, results warrant further investigation.